会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 24. 发明授权
    • Methods of treating vascular disease using an IL-1beta Antibody
    • 使用IL-1β抗体治疗血管疾病的方法
    • US09168298B2
    • 2015-10-27
    • US13955673
    • 2013-07-31
    • Hermann GramThomas Jung
    • Hermann GramThomas Jung
    • A61K39/395C07K16/24C07K16/00
    • C07K16/245A61K39/3955A61K2039/505C07K2317/21C07K2317/565C07K2317/76C07K2317/92
    • This invention relates to a novel use of IL-1□-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1□ ligand—IL-1 receptor interaction, IL-1□ antibodies or IL-1 receptor antibodies, e.g. IL-1□ binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1□ binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1□ ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.
    • 本发明涉及IL-1□配体/ IL-1受体破坏性化合物(本文中称为“IL-1β化合物”)的新用途。 例如破坏IL-1□配体-IL-1受体相互作用的小分子化合物,IL-1□抗体或IL-1受体抗体,例如。 本文所述的IL-1β结合分子,例如 本文公开的抗体,例如 IL-1β结合化合物或IL-1受体结合化合物和/或降低IL-1配体或IL-1受体蛋白水平的RNA化合物在治疗和/或预防自身炎症综合征中的作用。 少年类风湿性关节炎或成人类风湿性关节炎综合征以及治疗和/或预防自身炎症综合征的方法,例如, 少年类风湿关节炎或成人类风湿关节炎综合征,在哺乳动物,特别是人类。
    • 26. 发明申请
    • Methods of Treating Gout using IL-1beta Antagonists
    • 使用IL-1β拮抗剂治疗痛风的方法
    • US20120321642A1
    • 2012-12-20
    • US13587978
    • 2012-08-17
    • Hermann GramThomas Jung
    • Hermann GramThomas Jung
    • A61K39/395A61P19/02
    • C07K16/245A61K39/3955A61K2039/505C07K2317/21C07K2317/565C07K2317/76C07K2317/92
    • This invention relates to a novel use of IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1β ligand-IL-1 receptor interaction, IL-1β antibodies or IL-1 receptor antibodies, e.g. IL-1β binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1β binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1β ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.
    • 本发明涉及IL-1和bIG - 配体/ IL-1受体破坏化合物(本文中称为IL-1β化合物)的新用途; 例如破坏IL-1和bgr的小分子化合物; 配体-IL-1受体相互作用,IL-1和bgr; 抗体或IL-1受体抗体。 IL-1和bgr 本文所述的结合分子,例如。 本文公开的抗体,例如 IL-1和bgr 结合化合物或IL-1受体结合化合物,和/或降低IL-1和bgr的RNA化合物; 配体或IL-1受体蛋白水平,用于治疗和/或预防自身炎症综合征,例如, 少年类风湿性关节炎或成人类风湿性关节炎综合征以及治疗和/或预防自身炎症综合征的方法,例如, 少年类风湿关节炎或成人类风湿关节炎综合征,在哺乳动物,特别是人类。
    • 27. 发明授权
    • Method of treating an auto-inflammatory syndrome with a human IL-1β binding antibody
    • 用人IL-1和bgr治疗自身炎症综合征的方法 结合抗体
    • US08282922B2
    • 2012-10-09
    • US12601280
    • 2008-05-28
    • Hermann GramThomas Jung
    • Hermann GramThomas Jung
    • A61K39/395C07K16/00C12P21/08
    • C07K16/245A61K39/3955A61K2039/505C07K2317/21C07K2317/565C07K2317/76C07K2317/92
    • This invention relates to a novel use of IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1β ligand-IL-1 receptor interaction, IL-1β antibodies or IL-1 receptor antibodies, e.g. IL-1β binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1β binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1β ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.
    • 本发明涉及IL-1和bIG - 配体/ IL-1受体破坏化合物(本文中称为IL-1β化合物)的新用途; 例如破坏IL-1和bgr的小分子化合物; 配体-IL-1受体相互作用,IL-1和bgr; 抗体或IL-1受体抗体。 IL-1和bgr 本文所述的结合分子,例如。 本文公开的抗体,例如 IL-1和bgr 结合化合物或IL-1受体结合化合物,和/或降低IL-1和bgr的RNA化合物; 配体或IL-1受体蛋白水平,用于治疗和/或预防自身炎症综合征,例如, 少年类风湿性关节炎或成人类风湿性关节炎综合征以及治疗和/或预防自身炎症综合征的方法,例如, 少年类风湿关节炎或成人类风湿关节炎综合征,在哺乳动物,特别是人类。
    • 30. 发明申请
    • Indications for Anti-IL-1 Beta Therapy
    • 抗IL-1β治疗的适应症
    • US20100166750A1
    • 2010-07-01
    • US12601280
    • 2008-05-28
    • Hermann GramThomas Jung
    • Hermann GramThomas Jung
    • A61K39/395A61P19/02
    • C07K16/245A61K39/3955A61K2039/505C07K2317/21C07K2317/565C07K2317/76C07K2317/92
    • This invention relates to a novel use of IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1β ligand-IL-1 receptor interaction, IL-1β antibodies or IL-1 receptor antibodies, e.g. IL-1β binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1β binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1β ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.
    • 本发明涉及IL-1和bIG - 配体/ IL-1受体破坏化合物(本文中称为“IL-1β化合物”)的新用途。 例如破坏IL-1和bgr的小分子化合物; 配体-IL-1受体相互作用,IL-1和bgr; 抗体或IL-1受体抗体。 IL-1和bgr 本文所述的结合分子,例如。 本文公开的抗体,例如 IL-1和bgr 结合化合物或IL-1受体结合化合物,和/或降低IL-1和bgr的RNA化合物; 配体或IL-1受体蛋白水平,用于治疗和/或预防自身炎症综合征,例如, 少年类风湿性关节炎或成人类风湿性关节炎综合征以及治疗和/或预防自身炎症综合征的方法,例如, 少年类风湿关节炎或成人类风湿关节炎综合征,在哺乳动物,特别是人类。